Shanghai Sinobioway Sunterra Biotechnology ^Investors

Shanghai Sinobioway Sunterra Biotechnology is a leading organization in the field of adoptive cellular therapies. It was formed by Sinobioway Group, Sunterra Capital, and F1 Oncology with the goal of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. The organization's main focus is on cutting-edge biotechnology and it has established GMP cell processing facilities in Shanghai to support clinical research. SSSB has achieved significant milestones through key academic collaborations and is dedicated to advancing the field of cellular therapies.